Shares of Luminex Co. (NASDAQ:LMNX) have received a consensus rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.00.
Several equities analysts recently weighed in on LMNX shares. BidaskClub upgraded shares of Luminex from a “sell” rating to a “hold” rating in a report on Saturday. ValuEngine raised shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 12th. Finally, Zacks Investment Research raised shares of Luminex from a “strong sell” rating to a “hold” rating and set a $17.00 target price for the company in a research note on Tuesday, July 9th.
In other news, CEO Nachum Shamir bought 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was purchased at an average price of $19.71 per share, with a total value of $98,550.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.70% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its position in shares of Luminex by 0.6% during the first quarter. Rhumbline Advisers now owns 128,066 shares of the medical instruments supplier’s stock worth $2,947,000 after acquiring an additional 822 shares in the last quarter. Strs Ohio increased its position in shares of Luminex by 7.4% during the second quarter. Strs Ohio now owns 33,400 shares of the medical instruments supplier’s stock worth $689,000 after acquiring an additional 2,300 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Luminex by 22.6% during the second quarter. Fisher Asset Management LLC now owns 93,233 shares of the medical instruments supplier’s stock worth $1,924,000 after acquiring an additional 17,178 shares in the last quarter. Arizona State Retirement System increased its position in shares of Luminex by 1.2% during the second quarter. Arizona State Retirement System now owns 64,885 shares of the medical instruments supplier’s stock worth $1,339,000 after acquiring an additional 792 shares in the last quarter. Finally, RGM Capital LLC increased its position in shares of Luminex by 19.8% during the second quarter. RGM Capital LLC now owns 3,060,317 shares of the medical instruments supplier’s stock worth $63,165,000 after acquiring an additional 505,040 shares in the last quarter. 79.78% of the stock is owned by institutional investors.
NASDAQ LMNX traded down $0.06 during trading hours on Wednesday, hitting $22.31. The company’s stock had a trading volume of 609 shares, compared to its average volume of 158,473. The stock has a fifty day moving average of $20.87 and a 200 day moving average of $21.78. Luminex has a twelve month low of $19.41 and a twelve month high of $30.73. The firm has a market capitalization of $1.02 billion, a P/E ratio of 46.71 and a beta of 0.78. The company has a quick ratio of 2.45, a current ratio of 3.74 and a debt-to-equity ratio of 0.04.
Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.09). Luminex had a negative net margin of 0.80% and a negative return on equity of 0.78%. The business had revenue of $83.06 million during the quarter, compared to analyst estimates of $81.61 million. During the same quarter in the prior year, the company earned $0.15 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. On average, analysts predict that Luminex will post -0.17 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 17th. Shareholders of record on Thursday, September 26th will be paid a $0.09 dividend. This represents a $0.36 annualized dividend and a yield of 1.61%. The ex-dividend date is Wednesday, September 25th. This is an increase from Luminex’s previous quarterly dividend of $0.06. Luminex’s dividend payout ratio is presently 50.00%.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
See Also: Why do companies engage in swaps?
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.